The headline data from FLOW, a significant reduction in the primary outcome, is just the start of what we need to know
The deal also exemplifies the emergence of China's biotech sector as a major source of R&D candidates for pharma groups in the US and Europe, and Hengrui itself has previously signed big-ticket deals with MSD and Merck KGaA, amongst others.
They address different parts of the problem, which is why PT-141 is often discussed for patients who found blood flow medications ineffective or beside the point
Many save each month, even after factoring in the cost of the medication
Some research suggests splitting the dose (e.g., 1,000 mg in the morning with breakfast + 1,000 mg pre-workout) produces better muscle carnitine accumulation than a single large dose